Tsushima Takahiro, Tsuji Yasushi, Abe Seiichiro, Tanaka Shingo, Tamura Fumito, Mizushima Takeshi, Makino Kiyoko, Oura Kae, Honda Kana, Sumiyoshi Tetsuya, Yoshizaki Naohito, Kondo Hitoshi
Dept. of Medical Oncology, KKR Sapporo Medical Center Tonan Hospital.
Gan To Kagaku Ryoho. 2007 Oct;34(10):1647-50.
Docetaxel and paclitaxel are demonstrated to be effective for use as salvage therapy for advanced gastric cancer. Both drugs are taxane derivatives but there is only partial cross-resistance between them. For breast cancer and ovarian cancer, there have been several reports that showed docetaxel is effective for paclitaxel-resistant cancer, and vice versa. We experienced two cases of advanced gastric cancer effectively treated by sequential therapy of docetaxel and paclitaxel. One patient was a 43-year-old woman with a type 4 gastric carcinoma, and the other a 51-year-old woman who had suffered a recurrence of the gastric cancer after a total gastrectomy. At first, chemotherapy failed, so we chose docetaxel/high-dose 5-FU (HDFU) for the second-line therapy. After resistance to Docetaxel/HDFU, paclitaxel was effective for third-line treatment of both patients.